Chidamide plus R‐GDP for relapsed/refractory diffuse large B‐cell lymphoma in patients ineligible for autologous transplantation: A prospective, single‐arm, phase II study

Documenti analoghi

• Management of post‐autologous transplant relapse in patients with T‐cell lymphomas
  di: Olivier Veilleux, et al.
  Pubblicazione: (2024)
• A randomized trial of ibrutinib and R‐GDP prior to stem cell transplant in relapsed diffuse large B‐cell lymphoma
  di: John Kuruvilla, et al.
  Pubblicazione: (2024)
• Is universal CAR T‐cell referral absolutely required for transplant‐ineligible patients with primary refractory or early relapsed DLBCL ?
  di: Maria Dimou, et al.
  Pubblicazione: (2026)
• Prognostic significance of pretransplant 18 F ‐ FDG PET / CT metrics in relapsed/refractory diffuse large B‐cell lymphoma with partial response to salvage chemotherapy prior to autologous stem cell transplantation
  di: Minseung Suh, et al.
  Pubblicazione: (2025)
• Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre‐autologous stem cell transplant in relapsed/refractory diffuse large B‐cell lymphoma—outcome of rituximab‐dose‐intensive cyclophosphamide, etoposide, cisplatin (R‐DICEP) versus R‐GDP
  di: Douglas A. Stewart, et al.
  Pubblicazione: (2024)